Avrobio
Avrobio is a clinical-stage biotechnology company focused on developing innovative gene therapies to treat rare genetic diseases. Leveraging advanced lentiviral platform technology, Avrobio aims to deliver one-time, potentially curative treatments for conditions with significant unmet medical needs. The company’s pipeline includes investigational therapies targeting lysosomal disorders and other inherited diseases, with a commitment to improving patient outcomes through precision medicine. By integrating cutting-edge research and robust clinical development, Avrobio strives to transform the standard of care for individuals affected by rare genetic conditions. The company partners with leading institutions to advance its mission of bringing transformative gene therapies to patients worldwide.
